+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Glaucoma - Pipeline Review, H2 2019

  • ID: 4866568
  • Drug Pipelines
  • November 2019
  • Region: Global
  • 340 pages
  • Global Markets Direct
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 3

FEATURED COMPANIES

  • AC Immune SA
  • Cellix Bio Pvt Ltd
  • Future Medicine Co Ltd
  • LayerBio Inc
  • Novartis AG
  • Q BioMed Inc
  • MORE
Glaucoma - Pipeline Review, H2 2019

Summary

This latest Pharmaceutical and Healthcare disease pipeline guide Glaucoma - Pipeline Review, H2 2019, provides an overview of the Glaucoma (Ophthalmology) pipeline landscape.

Glaucoma is a disease of the eye in which fluid pressure within the eye rises. The exact cause of optic nerve damage from glaucoma is not fully understood, but involves mechanical compression and/or decreased blood flow of the optic nerve. The most important risk factors include age, elevated eye pressure, African ancestry, thin cornea, family history of glaucoma. Signs and symptoms include eye pain, nausea and vomiting (accompanying the severe eye pain), sudden onset of visual disturbance, often in low light, blurred vision and reddening of the eye.

Report Highlights

This Pharmaceutical and Healthcare latest pipeline guide Glaucoma - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Glaucoma (Ophthalmology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Glaucoma (Ophthalmology) pipeline guide also reviews of key players involved in therapeutic development for Glaucoma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 4, 12, 18, 10, 3, 67, 14 and 4 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 12 and 3 molecules, respectively.

Glaucoma (Ophthalmology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher'sproprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Glaucoma (Ophthalmology).
  • The pipeline guide reviews pipeline therapeutics for Glaucoma (Ophthalmology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Glaucoma (Ophthalmology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Glaucoma (Ophthalmology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Glaucoma (Ophthalmology)
Reasons to buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Glaucoma (Ophthalmology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Glaucoma (Ophthalmology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • AC Immune SA
  • Cellix Bio Pvt Ltd
  • Future Medicine Co Ltd
  • LayerBio Inc
  • Novartis AG
  • Q BioMed Inc
  • MORE
Introduction
Glaucoma - Overview
Glaucoma - Therapeutics Development
Glaucoma - Therapeutics Assessment
Glaucoma - Companies Involved in Therapeutics Development
Glaucoma - Drug Profiles
Glaucoma - Dormant Projects
Glaucoma - Discontinued Products
Glaucoma - Product Development Milestones
Appendix

List of Tables
Table 1: Number of Products under Development for Glaucoma, H2 2019
Table 2: Number of Products under Development by Companies, H2 2019
Table 3: Number of Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Table 4: Number of Products under Development by Companies, H2 2019 (Contd..2), H2 2019
Table 5: Number of Products under Development by Companies, H2 2019 (Contd..3), H2 2019
Table 6: Number of Products under Development by Companies, H2 2019 (Contd..4), H2 2019
Table 7: Number of Products under Development by Universities/Institutes, H2 2019
Table 8: Products under Development by Companies, H2 2019
Table 9: Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Table 10: Products under Development by Companies, H2 2019 (Contd..2), H2 2019
Table 11: Products under Development by Companies, H2 2019 (Contd..3), H2 2019
Table 12: Products under Development by Companies, H2 2019 (Contd..4), H2 2019
Table 13: Products under Development by Companies, H2 2019 (Contd..5), H2 2019
Table 14: Products under Development by Companies, H2 2019 (Contd..6), H2 2019
Table 15: Products under Development by Companies, H2 2019 (Contd..7), H2 2019
Table 16: Products under Development by Universities/Institutes, H2 2019
Table 17: Number of Products by Stage and Target, H2 2019
Table 18: Number of Products by Stage and Target, H2 2019 (Contd..1), H2 2019
Table 19: Number of Products by Stage and Target, H2 2019 (Contd..2), H2 2019
Table 20: Number of Products by Stage and Target, H2 2019 (Contd..3), H2 2019
Table 21: Number of Products by Stage and Mechanism of Action, H2 2019
Table 22: Number of Products by Stage and Mechanism of Action, H2 2019 (Contd..1), H2 2019
Table 23: Number of Products by Stage and Mechanism of Action, H2 2019 (Contd..2), H2 2019
Table 24: Number of Products by Stage and Mechanism of Action, H2 2019 (Contd..3), H2 2019
Table 25: Number of Products by Stage and Route of Administration, H2 2019
Table 26: Number of Products by Stage and Molecule Type, H2 2019
Table 27: Glaucoma - Pipeline by AC Immune SA, H2 2019
Table 28: Glaucoma - Pipeline by Acorn Biomedical Inc, H2 2019
Table 29: Glaucoma - Pipeline by Aerie Pharmaceuticals Inc, H2 2019
Table 30: Glaucoma - Pipeline by Aerpio Pharmaceuticals Inc, H2 2019
Table 31: Glaucoma - Pipeline by Allergan Plc, H2 2019
Table 32: Glaucoma - Pipeline by Amarantus Bioscience Holdings Inc, H2 2019
Table 33: Glaucoma - Pipeline by Amgen Inc, H2 2019
Table 34: Glaucoma - Pipeline by Annexon Inc, H2 2019
Table 35: Glaucoma - Pipeline by Ascentage Pharma Group International, H2 2019
Table 36: Glaucoma - Pipeline by Asha Vision LLC, H2 2019
Table 37: Glaucoma - Pipeline by Betaliq Inc, H2 2019
Table 38: Glaucoma - Pipeline by Bial - Portela & Ca SA, H2 2019
Table 39: Glaucoma - Pipeline by BioAxone BioSciences Inc, H2 2019
Table 40: Glaucoma - Pipeline by Califia Bio Inc, H2 2019
Table 41: Glaucoma - Pipeline by Calpain Therapeutics Pty Ltd, H2 2019
Table 42: Glaucoma - Pipeline by Cellix Bio Pvt Ltd, H2 2019
Table 43: Glaucoma - Pipeline by Certa Therapeutics Pty Ltd, H2 2019
Table 44: Glaucoma - Pipeline by Chong Kun Dang Pharmaceutical Corp, H2 2019
Table 45: Glaucoma - Pipeline by D. Western Therapeutics Institute Inc, H2 2019
Table 46: Glaucoma - Pipeline by Deha Pharmaceutical LLC, H2 2019
Table 47: Glaucoma - Pipeline by Dhp Korea Ltd, H2 2019
Table 48: Glaucoma - Pipeline by Disarm Therapeutics Inc, H2 2019
Table 49: Glaucoma - Pipeline by Dompe Farmaceutici SpA, H2 2019
Table 50: Glaucoma - Pipeline by Emerald Bioscience Inc, H2 2019
Table 51: Glaucoma - Pipeline by Envisia Therapeutics Inc, H2 2019
Table 52: Glaucoma - Pipeline by Evotec SE, H2 2019
Table 53: Glaucoma - Pipeline by Eyenovia Inc, H2 2019
Table 54: Glaucoma - Pipeline by EyePoint Pharmaceuticals Inc, H2 2019
Table 55: Glaucoma - Pipeline by Eyevensys SAS, H2 2019
Table 56: Glaucoma - Pipeline by Fortress Biotech Inc, H2 2019
Table 57: Glaucoma - Pipeline by Future Medicine Co Ltd, H2 2019
Table 58: Glaucoma - Pipeline by Galimedix Therapeutics Ltd, H2 2019
Table 59: Glaucoma - Pipeline by Gene Signal International SA, H2 2019
Table 60: Glaucoma - Pipeline by Glaukos Corp, H2 2019

List of Figures
Figure 1: Number of Products under Development for Glaucoma, H2 2019
Figure 2: Number of Products under Development by Companies, H2 2019
Figure 3: Number of Products under Development by Universities/Institutes, H2 2019
Figure 4: Number of Products by Top 10 Targets, H2 2019
Figure 5: Number of Products by Stage and Top 10 Targets, H2 2019
Figure 6: Number of Products by Top 10 Mechanism of Actions, H2 2019
Figure 7: Number of Products by Stage and Top 10 Mechanism of Actions, H2 2019
Figure 8: Number of Products by Top 10 Routes of Administration, H2 2019
Figure 9: Number of Products by Stage and Top 10 Routes of Administration, H2 2019
Figure 10: Number of Products by Top 10 Molecule Types, H2 2019
Figure 11: Number of Products by Stage and Top 10 Molecule Types, H2 2019
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • AC Immune SA
  • Acorn Biomedical Inc
  • Aerie Pharmaceuticals Inc
  • Aerpio Pharmaceuticals Inc
  • Allergan Plc
  • Amarantus Bioscience Holdings Inc
  • Amgen Inc
  • Annexon Inc
  • Ascentage Pharma Group International
  • Asha Vision LLC
  • Betaliq Inc
  • Bial - Portela & Ca SA
  • BioAxone BioSciences Inc
  • Califia Bio Inc
  • Calpain Therapeutics Pty Ltd
  • Cellix Bio Pvt Ltd
  • Certa Therapeutics Pty Ltd
  • Chong Kun Dang Pharmaceutical Corp
  • D. Western Therapeutics Institute Inc
  • Deha Pharmaceutical LLC
  • Dhp Korea Ltd
  • Disarm Therapeutics Inc
  • Dompe Farmaceutici SpA
  • Emerald Bioscience Inc
  • Envisia Therapeutics Inc
  • Evotec SE
  • Eyenovia Inc
  • EyePoint Pharmaceuticals Inc
  • Eyevensys SAS
  • Fortress Biotech Inc
  • Future Medicine Co Ltd
  • Galimedix Therapeutics Ltd
  • Gene Signal International SA
  • Glaukos Corp
  • Graybug Vision Inc
  • Guangzhou Cellprotek Pharmaceutical Co Ltd
  • Guangzhou Magpie Pharmaceutical Co Ltd
  • Handok Inc
  • HitGen LTD
  • ID Pharma Co Ltd
  • InMed Pharmaceuticals Inc
  • Inspyr Therapeutics Inc
  • Isarna Therapeutics GmbH
  • Kodiak Sciences Inc
  • Kukje Pharmaceutical Industry Co Ltd
  • Kyoto Drug Discovery & Development Co Ltd
  • Laboratorios SALVAT SA
  • Laboratorios Sophia SA de CV
  • LayerBio Inc
  • Lee's Pharmaceutical Holdings Ltd
  • Matrix Biomed Inc
  • MimeTech Srl
  • MyX Therapeutics Inc
  • Nanoscope Therapeutics Inc
  • NeuBase Therapeutics Inc
  • NeurAegis Inc
  • Neurim Pharmaceuticals Ltd
  • Neurizon Pharma GBR
  • Neuroptika Inc
  • NicOx SA
  • NoNO Inc
  • Novaliq GmbH
  • Novartis AG
  • Noveome Biotherapeutics Inc
  • Novoron Bioscience Inc
  • Ocular Therapeutix Inc
  • Oculo Therapy LLC
  • Ocuphire Pharma Inc
  • Oncolys BioPharma Inc
  • ONL Therapeutics Inc
  • Palo BioFarma SL
  • pH Pharma Co Ltd
  • Pivot Pharmaceuticals Inc
  • Profarma
  • Q BioMed Inc
  • Qlaris Bio Inc
  • Quark Pharmaceuticals Inc
  • Quethera Ltd
  • Qurgen Inc
  • Radikal Therapeutics Inc
  • Regeneron Pharmaceuticals Inc
  • ReNetX Bio
  • Santen Pharmaceutical Co Ltd
  • Senju Pharmaceutical Co Ltd
  • Sun Pharma Advanced Research Company Ltd
  • Sustained Nano Systems LLC
  • Suzhou Ribo Life Sciences Co Ltd
  • Sylentis SAU
  • Taejoon Pharm Co Ltd
  • Takeda Pharmaceutical Co Ltd
  • Teraclon IDF SL
  • TikoMed AB
  • Toa Eiyo Ltd
  • ViSci Ltd
  • Whitecap Biosciences LLC
Note: Product cover images may vary from those shown
Adroll
adroll